Jeffrey A Lieberman

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
  2. ncbi request reprint Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
  3. ncbi request reprint Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
  4. ncbi request reprint Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
  5. ncbi request reprint Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:1050-60. 2007
  6. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
  7. ncbi request reprint Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
    Biol Psychiatry 59:97-105. 2006
  8. pmc The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial
    David L Penn
    University of North Carolina Chapel Hill, Department of Psychology, Davie Hall, Chapel Hill, NC 27599 3270, USA
    Schizophr Res 115:17-23. 2009
  9. ncbi request reprint Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
  10. pmc Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type
    Robert K McClure
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
    Psychiatry Res 211:1-10. 2013

Detail Information

Publications110 found, 100 shown here

  1. ncbi request reprint Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
    ..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
  2. ncbi request reprint Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  3. ncbi request reprint Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
    ..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic...
  4. ncbi request reprint Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
    ..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
  5. ncbi request reprint Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:1050-60. 2007
    ....
  6. ncbi request reprint Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C B 7160, University of North Carolina School of Medicine, Chapel Hill, 27599 7160, USA
    Schizophr Res 83:53-63. 2006
    ..Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects...
  7. ncbi request reprint Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
    Biol Psychiatry 59:97-105. 2006
    ..Neurocognitive deficits are severe in first-episode psychosis...
  8. pmc The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial
    David L Penn
    University of North Carolina Chapel Hill, Department of Psychology, Davie Hall, Chapel Hill, NC 27599 3270, USA
    Schizophr Res 115:17-23. 2009
    ..Greater improvement in emotion perception at 2 months was significantly predicted by lower baseline emotion perception and higher baseline neurocognitive functioning, and marginally predicted by less time on an antipsychotic...
  9. ncbi request reprint Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
    ..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
  10. pmc Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type
    Robert K McClure
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
    Psychiatry Res 211:1-10. 2013
    ..Treatment-related related longitudinal shape change was not observed within the studied timeframe. Our results provide additional evidence for disrupted cortico-basal ganglia-thalamo-cortical circuits in schizophrenia...
  11. ncbi request reprint A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial
    Linmarie Sikich
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 29:133-45. 2004
    ..However, youth treated with risperidone and olanzapine experienced weight gain and extrapyramidal effects that appear more prevalent and severe than reported in adults...
  12. ncbi request reprint Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia
    Miranda H Chakos
    University of North Carolina at Chapel Hill CB 7160, Chapel Hill, North Carolina 27599 7160, USA
    Br J Psychiatry 186:26-31. 2005
    ..Reduced hippocampal volume is a consistently described structural abnormality in schizophrenia but its cause and timing are not known...
  13. ncbi request reprint Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 32:95-102. 2007
    ..Although the association between antipsychotic treatment and increased pro-apoptotic caspase-3 is intriguing, further study is needed to understand its potential effects...
  14. pmc Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression
    Leisa A Glantz
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Schizophr Res 118:292-9. 2010
    ..Changes in the Par-4/D2DR signaling pathway represent a novel mechanism that may link apoptotic and dopamine signaling pathways in major depression and schizophrenia...
  15. ncbi request reprint Neurocognition in early-onset schizophrenia and schizoaffective disorders
    Stephen R Hooper
    The Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7255, USA
    J Am Acad Child Adolesc Psychiatry 49:52-60. 2010
    ....
  16. pmc No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition
    Thomas I Konneker
    Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7264, USA
    Am J Med Genet B Neuropsychiatr Genet 153:1115-7. 2010
    ..67 and negative symptoms P = 0.46). We were unable to identify association of the triallelic 5-HTTLPR with schizophrenia, neurocognition, or core psychotic symptoms even at levels of significance unadjusted for multiple comparisons...
  17. ncbi request reprint Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, CB 7160, Chapel Hill, NC 27599, USA
    Am J Psychiatry 162:1785-804. 2005
    ..The authors reviewed the literature on the association of duration of untreated psychosis with symptom severity at first treatment contact and with treatment outcomes and conducted a meta-analysis examining these relationships...
  18. ncbi request reprint Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity
    Samantha S Gizerian
    Curriculum in Neurobiology and Department of Psychiatry, University of North Carolina at Chapel Hill, 7023 Neurosciences Hospital, Chapel Hill, NC 27599, USA
    Psychopharmacology (Berl) 186:334-42. 2006
    ..p.) alters the localization of prefrontal cortex (PFC) interneurons in adulthood. Such displacement could result in disinhibited behavior associated with impaired development of the mesocortical dopamine system...
  19. ncbi request reprint Apoptotic mechanisms and the synaptic pathology of schizophrenia
    Leisa A Glantz
    Department of Psychiatry, University of North Carolina Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Schizophr Res 81:47-63. 2006
    ..This paper will review converging lines of data that implicate synaptic deficits in the pathophysiology of schizophrenia and propose an underlying role for apoptotic dysregulation...
  20. ncbi request reprint Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, North Carolina 27599 7160, USA
    Nat Rev Drug Discov 5:133-46. 2006
    ..Practical and large, simple trials that evaluate the comparative effectiveness of antipsychotic drugs in real-world settings can help to meet these needs once a drug has reached the market...
  21. pmc Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC, USA
    Neuropsychopharmacology 38:1245-52. 2013
    ..Future clinical and preclinical studies are needed to fully define the mechanism of action and cognitive effects of davunetide in schizophrenia...
  22. ncbi request reprint Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
    Karen A Graham
    Department of Psychiatry, CB 7160, UNC Neurosciences Hospital, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 162:1744-6. 2005
    ..This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine...
  23. pmc Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing
    Rajendra A Morey
    Duke UNC Brain Imaging and Analysis Center, Durham, NC, USA
    Arch Gen Psychiatry 62:254-62. 2005
    ..The neurobiological underpinnings of such executive deficits in ultra-high-risk individuals remains unclear...
  24. pmc Attentional modulation of early-stage visual processing in schizophrenia
    Odin van der Stelt
    Department of Psychiatry, University of North Carolina, School of Medicine, Chapel Hill, NC 28223, USA
    Brain Res 1125:194-8. 2006
    ..These results suggest that a relatively early stage of visual-selective processing in posterior extrastriate cortex is disrupted in schizophrenia...
  25. ncbi request reprint Revised PORT recommendations
    T Scott Stroup
    University of North Carolina at Chapel Hill, 10626 Neurosciences Hospital, Campus Box 7160, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 30:609-11. 2004
  26. ncbi request reprint Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies
    R Grant Steen
    Department of Psychiatry, University of North Carolina at Chapel Hill, Campus Box 7160, Chapel Hill, North Carolina 27599 7160, USA
    Br J Psychiatry 188:510-8. 2006
    ..Studies of people with schizophrenia assessed using magnetic resonance imaging (MRI) usually include patients with first-episode and chronic disease, yet brain abnormalities may be limited to those with chronic schizophrenia...
  27. ncbi request reprint Neuroprotection in schizophrenia
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 67:e09. 2006
    ....
  28. ncbi request reprint Schizophrenia: new pathological insights and therapies
    L Fredrik Jarskog
    Department of Psychiatry, Schizophrenia Research Center, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Annu Rev Med 58:49-61. 2007
    ..This review provides an update on developments in research on the neuropathology of schizophrenia and discusses recent advances in antipsychotic treatment and the potential impact on long-term outcomes...
  29. pmc Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors
    Martin Styner
    Department of Computer Science, University of North Carolina, Chapel Hill, NC 27599 3175, USA
    Proc Natl Acad Sci U S A 102:4872-7. 2005
    ..Our results suggest that genetics have a stronger influence on the shape of lateral ventricles than do the disease-related changes in schizophrenia...
  30. ncbi request reprint Psychosocial treatment for first-episode psychosis: a research update
    David L Penn
    Department of Psychology, CB 3270, Davie Hall, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 3270, USA
    Am J Psychiatry 162:2220-32. 2005
    ..This article reviews research on psychosocial treatment for first-episode psychosis...
  31. pmc A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial
    Huei Ting Tsai
    Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Med Genet B Neuropsychiatr Genet 153:336-40. 2010
    ..No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature...
  32. pmc Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain
    John H Gilmore
    UNC Schizophrenia Research Center and Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Neurosci 27:1255-60. 2007
    ..These findings also indicate that whereas some adult patterns of sexual dimorphism and cerebral asymmetries are present at birth, others develop after birth...
  33. pmc No evidence for parental imprinting of mouse 22q11 gene orthologs
    Thomas M Maynard
    UNC Silvio O Conte Center for the Neuroscience of Mental Disorders, University of North Carolina, Chapel Hill, North Carolina, 27599, USA
    Mamm Genome 17:822-32. 2006
    ..Given the high degree of similarity of human 22q11 and the orthologous region of mmChr16, genomic imprinting most likely cannot explain apparent parent-of-origin effects in 22q11DS...
  34. pmc Macroscopic fast neuronal oscillations and synchrony in schizophrenia
    Odin van der Stelt
    Department of Psychiatry, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    Proc Natl Acad Sci U S A 101:17567-8. 2004
  35. ncbi request reprint Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation
    Gary E Duncan
    Department of Psychiatry, CB 7090, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7250, USA
    J Pharmacol Exp Ther 305:999-1005. 2003
    ....
  36. ncbi request reprint Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine
    Jeffrey A Lieberman
    Department of Psychiatry, CB 7160, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 28:995-1003. 2003
    ..Longer duration of untreated psychosis was associated with lower odds of achieving remission...
  37. ncbi request reprint Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features
    Sayed S Alamy
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
    Schizophr Res 66:183-6. 2004
    ..The case illustrates the potential role of secretin as a novel adjunctive treatment strategy in schizophrenic patients with autistic features...
  38. ncbi request reprint Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function
    Gary E Duncan
    Department of Psychiatry, University of North Carolina School of Medicine, CB 7090, Chapel Hill, NC 27599 7090, USA
    Behav Brain Res 153:507-19. 2004
    ..The NR1 hypomorphic mice could represent a model system to explore novel treatment and preventative strategies for certain symptoms of schizophrenia...
  39. ncbi request reprint The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development
    T Scott Stroup
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill 27599 7160, USA
    Schizophr Bull 29:15-31. 2003
    ..If the phase 2 study drug is discontinued, subjects may enter phase 3, in which clinicians help subjects select an open-label treatment based on individuals' experiences in phases 1 and 2...
  40. doi request reprint Aripiprazole versus haloperidol treatment in early-stage schizophrenia
    Ragy R Girgis
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    J Psychiatr Res 45:756-62. 2011
    ..However, excessive dosing of the antipsychotic medications, in particular haloperidol, may have played an important role in accounting for the differences between aripiprazole and haloperidol in this study...
  41. ncbi request reprint Myocarditis during clozapine treatment
    David B Merrill
    Department of Psychiatry, New York State Psychiatric Institute, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA corrected
    Am J Psychiatry 163:204-8. 2006
  42. doi request reprint Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 4, New York, NY 10032, USA
    Pharmacol Rev 60:358-403. 2008
    ....
  43. ncbi request reprint Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  44. doi request reprint A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Neuropsychopharmacology 34:1322-9. 2009
    ..6 and 3.0% of patients in these groups, respectively. Memantine showed no efficacy as an adjunctive therapy in schizophrenia patients with residual psychopathology and was associated with a higher incidence of AEs than placebo...
  45. doi request reprint Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state
    Susan M Essock
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York City, USA
    Psychiatr Serv 60:1595-602. 2009
    ..This study sought to identify and characterize rates of clinically questionable prescribing in New York State...
  46. ncbi request reprint Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    Arch Gen Psychiatry 63:1069-72. 2006
  47. pmc Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology
    David Kimhy
    Department of Psychiatry, Box 55, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
    Schizophr Bull 36:1131-9. 2010
    ..Our aim is to the test the feasibility and validity of a novel methodology designed to measure concurrent stress and arousal in individuals with psychosis during "real-world" daily functioning...
  48. pmc Teaching trainees to negotiate research collaborations with industry: a mentorship model
    David B Merrill
    Department of Psychiatry, Columbia University, College of Physicians, NY 10032, USA
    Am J Psychiatry 167:381-6. 2010
    ....
  49. doi request reprint Science and recovery in schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Psychiatr Serv 59:487-96. 2008
    ..Future clinical and neuroscience research and service development should emphasize measures of recovery as outcomes for people with schizophrenia...
  50. pmc Presynaptic regulation of dopamine transmission in schizophrenia
    Gholson J Lyon
    Department of Psychiatry, Columbia University, New York City, NY 10032, USA
    Schizophr Bull 37:108-17. 2011
    ..New laboratory approaches are elucidating mechanisms that control the level of presynaptic DA stores, thus contributing to fundamental understanding of the basic pathophysiologic mechanism in schizophrenia...
  51. ncbi request reprint Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation
    L Fredrik Jarskog
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599 7160, USA
    Am J Psychiatry 161:109-15. 2004
    ..It was hypothesized that the Bax/Bcl-2 ratio, but not caspase-3, would be high in the temporal cortex of patients with chronic schizophrenia...
  52. ncbi request reprint Dopamine partial agonists: a new class of antipsychotic
    Jeffrey A Lieberman
    University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7160, USA
    CNS Drugs 18:251-67. 2004
    ..In conclusion, the findings from clinical studies of aripiprazole show that dopamine partial agonists offer a novel, effective and well-tolerated treatment approach for patients with schizophrenia...
  53. ncbi request reprint Pharmacological management of first-episode schizophrenia and related nonaffective psychoses
    Daniel W Bradford
    University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill, North Carolina 27599 7160, USA
    Drugs 63:2265-83. 2003
    ..Future research will further define their roles in treatment and hopefully identify targets for prevention of first-episode schizophrenia...
  54. ncbi request reprint Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs
    Candace Andersson
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
    Neuropsychopharmacology 27:143-51. 2002
    ..The current data suggests that such differential responses may be due to both the pharmacological properties and the relative doses of the atypical agents...
  55. ncbi request reprint Apoptotic mechanisms in the pathophysiology of schizophrenia
    L Fredrik Jarskog
    Department of Psychiatry, Schizophrenia Research Center, University of North Carolina Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Prog Neuropsychopharmacol Biol Psychiatry 29:846-58. 2005
    ..Although the exact role of apoptosis in schizophrenia remains uncertain, the potential involvement of non-lethal localized apoptosis is intriguing, especially in earlier stages of the illness...
  56. ncbi request reprint Boundary and medial shape analysis of the hippocampus in schizophrenia
    Martin Styner
    Department of Computer Science, University of North Carolina at Chapel Hill, CB 3175, Sitterson Hall, Chapel Hill, NC 27599 317, USA
    Med Image Anal 8:197-203. 2004
    ..The results strongly suggest that the normalized hippocampal shape of the schizophrenic group is different from the control group, most significantly as a deformation difference in the tail region...
  57. ncbi request reprint Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia
    Odin van der Stelt
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
    Arch Gen Psychiatry 61:237-48. 2004
    ....
  58. ncbi request reprint Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis
    R Grant Steen
    Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 30:1949-62. 2005
    ..Only three of 64 studies included enough subjects to have 80% power to detect a 10% NAA reduction in patients, and no studies were adequately powered to detect a 5% NAA reduction with 80% power...
  59. ncbi request reprint 22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome
    Thomas M Maynard
    Department of Cell and Molecular Physiology, CB 7545, UNC School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    Int J Dev Neurosci 20:407-19. 2002
    ....
  60. ncbi request reprint Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care?
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, Neurosciences Hospital, Chapel Hill, NC 27599 7160, USA
    Schizophr Bull 29:1-6. 2003
  61. ncbi request reprint Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats
    Samantha S Gizerian
    Curriculum in Neurobiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Brain Res 1012:66-74. 2004
    ....
  62. ncbi request reprint Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex
    A Chistina Grobin
    Department of Psychiatry, and Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7178, USA
    J Neurosci 23:1832-9. 2003
    ..These data are consistent with a change in the distribution of a subset of interneurons in response to neurosteroid exposure and suggest that GABAergic neurosteroids are critical for normal development of GABAergic systems in the PFC...
  63. ncbi request reprint Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia
    Rita Z Goldstein
    Brookhaven National Laboratory, Upton, New York 11973, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:88-98. 2002
    ..To examine the independent contribution of executive versus semantic function to improvement in formal thought disorder after initial stabilization in a first-episode sample...
  64. doi request reprint The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC 27710, United States
    Schizophr Res 100:39-52. 2008
    ..This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances...
  65. ncbi request reprint Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics
    Jean A Frazier
    Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA
    J Am Acad Child Adolesc Psychiatry 46:979-88. 2007
    ..We examined baseline demographic and clinical profiles of youths enrolled from 2001 to 2006 in the publicly funded multicenter, randomized controlled trial Treatment of Early-Onset Schizophrenia Spectrum Disorders...
  66. doi request reprint Relationship of cognition and psychopathology to functional impairment in schizophrenia
    Somaia Mohamed
    New England Mental Illness, Research, Education and Clinical Center, Department of Veterans Affairs, West Haven, Conn 06516, USA
    Am J Psychiatry 165:978-87. 2008
    ..This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)...
  67. pmc Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Psychiatry 165:844-54. 2008
    ..The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior...
  68. ncbi request reprint Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods
    Jon McClellan
    University of Washington, Seattle, USA
    J Am Acad Child Adolesc Psychiatry 46:969-78. 2007
    ..The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described...
  69. ncbi request reprint Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
    Jean Pierre Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    J Clin Psychiatry 63:931-5. 2002
    ....
  70. ncbi request reprint Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents
    Christine E Marx
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27705, USA
    Neuropsychopharmacology 28:1-13. 2003
    ..Alterations in this neuroactive steroid may result in the modulation of GABAergic and dopaminergic neurotransmission, potentially contributing to antipsychotic efficacy...
  71. ncbi request reprint Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
    ..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis...
  72. ncbi request reprint Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder
    Delbert G Robinson
    Department of Psychiatry Research, Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Schizophr Res 57:209-19. 2002
    ..Although extensively studied in multi-episode patients, little data exist on medication adherence by first-episode patients...
  73. ncbi request reprint Antipsychotic-induced weight gain and therapeutic response: a differential association
    Pal Czobor
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    J Clin Psychopharmacol 22:244-51. 2002
    ..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
  74. ncbi request reprint Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study
    Linmarie Sikich
    University of North Carolina at Chapel Hill, NC 27514, USA
    Am J Psychiatry 165:1420-31. 2008
    ....
  75. doi request reprint Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  76. doi request reprint What CATIE found: results from the schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Psychiatr Serv 59:500-6. 2008
    ..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices...
  77. ncbi request reprint Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  78. pmc Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  79. pmc Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
    Jeffrey W Swanson
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 905 West Main Street, Durham, NC 27710, USA
    Br J Psychiatry 193:37-43. 2008
    ..Violence is an uncommon but significant problem associated with schizophrenia...
  80. ncbi request reprint Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  81. ncbi request reprint Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia
    Jeffrey A Lieberman
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    CNS Spectr 12:1-13; quiz 14. 2007
    ..Finally, L. Fredrik Jarskog, MD, focuses on the neurobiology of functional progression in schizophrenia as well as pharmacology and the potential for neuroprotection...
  82. ncbi request reprint Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  83. pmc Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 140:133-45. 2005
    ..Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects...
  84. ncbi request reprint Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  85. ncbi request reprint First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol
    Alan I Green
    Commonwealth Research Center and the Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
    Schizophr Res 66:125-35. 2004
    ..We report on rates of co-occurring substance use disorders in patients within their first episode of schizophrenia-related psychosis from a multicenter, international treatment trial of olanzapine vs. haloperidol...
  86. ncbi request reprint Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....
  87. ncbi request reprint COMT158 polymorphism and hostility
    Jan Volavka
    Nathan Kline Institute, Orangeburg, New York 10982, USA
    Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004
    ..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
  88. ncbi request reprint Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode
    Stephen M Strakowski
    Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0583, Cincinnati, OH 45267 0583, USA
    Schizophr Res 78:161-9. 2005
    ..This improvement is particularly relevant early in the course of schizophrenia...
  89. ncbi request reprint Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation
    Jan Volavka
    Schizophr Res 76:127-9. 2005
  90. ncbi request reprint The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
    Neurosci Lett 379:81-9. 2005
    ..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
  91. ncbi request reprint Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  92. ncbi request reprint Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Am J Psychiatry 161:985-95. 2004
    ..This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis...
  93. ncbi request reprint Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
  94. ncbi request reprint Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects
    Rael D Strous
    Chronic Impatient Department, Beer Yaakov Mental Health Center, Tel Aviv University, Tel Aviv, Israel
    Schizophr Bull 30:265-78. 2004
    ..Measures of premorbid functioning indicate that disease pathogenesis is manifest, albeit more subtly, prior to presentation of first psychotic symptoms...
  95. ncbi request reprint Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    Robert B Zipursky
    Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Br J Psychiatry 187:537-43. 2005
    ..Substantial weight gain is common with many atypical antipsychotics...
  96. ncbi request reprint From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  97. ncbi request reprint Interpreting the results of the CATIE study
    Jeffrey A Lieberman
    Psychiatr Serv 57:139. 2006
  98. ncbi request reprint Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  99. ncbi request reprint Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia
    Todd Lencz
    Department of Psychiatry, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Arch Gen Psychiatry 60:238-43. 2003
    ..It was hypothesized that patients in the first episode of schizophrenia would exhibit dissociable deficits in both WM domains...
  100. ncbi request reprint Effectiveness of switching antipsychotic medications
    Susan M Essock
    Department of Psychiatry, Division of Health Services Research, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Psychiatry 163:2090-5. 2006
    ....
  101. ncbi request reprint Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    N Engl J Med 355:1525-38. 2006
    ..We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease...